current continuous glucose monitors Search Results


continuous glucose monitoring cgm devices  (Abbott Laboratories)
86
Abbott Laboratories continuous glucose monitoring cgm devices
Continuous Glucose Monitoring Cgm Devices, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring cgm devices/product/Abbott Laboratories
Average 86 stars, based on 1 article reviews
continuous glucose monitoring cgm devices - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
continuous glucose monitoring  (Human Kinetics Inc)
90
Human Kinetics Inc continuous glucose monitoring
Continuous Glucose Monitoring, supplied by Human Kinetics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring/product/Human Kinetics Inc
Average 90 stars, based on 1 article reviews
continuous glucose monitoring - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
continuous glucose monitoring system (cgms)  (MiniMed Inc)
90
MiniMed Inc continuous glucose monitoring system (cgms)
Continuous Glucose Monitoring System (Cgms), supplied by MiniMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring system (cgms)/product/MiniMed Inc
Average 90 stars, based on 1 article reviews
continuous glucose monitoring system (cgms) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
regulated devices like wearable continuous glucose monitors  (RenderX Inc)
90
RenderX Inc regulated devices like wearable continuous glucose monitors
Regulated Devices Like Wearable Continuous Glucose Monitors, supplied by RenderX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/regulated devices like wearable continuous glucose monitors/product/RenderX Inc
Average 90 stars, based on 1 article reviews
regulated devices like wearable continuous glucose monitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
continuous glucose monitor (cgm) device  (Meiqi Trading Co)
90
Meiqi Trading Co continuous glucose monitor (cgm) device
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Monitor (Cgm) Device, supplied by Meiqi Trading Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitor (cgm) device/product/Meiqi Trading Co
Average 90 stars, based on 1 article reviews
continuous glucose monitor (cgm) device - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
continuous intravascular glucose monitoring system (cigms)  (GlySure Ltd)
90
GlySure Ltd continuous intravascular glucose monitoring system (cigms)
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Intravascular Glucose Monitoring System (Cigms), supplied by GlySure Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous intravascular glucose monitoring system (cigms)/product/GlySure Ltd
Average 90 stars, based on 1 article reviews
continuous intravascular glucose monitoring system (cigms) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
continuous glucose monitoring system  (Senseonics)
90
Senseonics continuous glucose monitoring system
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Monitoring System, supplied by Senseonics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring system/product/Senseonics
Average 90 stars, based on 1 article reviews
continuous glucose monitoring system - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
minilinktm real-time transmitter continuous glucose monitoring system (rt-cgms)  (MiniMed Inc)
90
MiniMed Inc minilinktm real-time transmitter continuous glucose monitoring system (rt-cgms)
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Minilinktm Real Time Transmitter Continuous Glucose Monitoring System (Rt Cgms), supplied by MiniMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/minilinktm real-time transmitter continuous glucose monitoring system (rt-cgms)/product/MiniMed Inc
Average 90 stars, based on 1 article reviews
minilinktm real-time transmitter continuous glucose monitoring system (rt-cgms) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ipro continuous glucose monitoring systems  (MiniMed Inc)
90
MiniMed Inc ipro continuous glucose monitoring systems
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Ipro Continuous Glucose Monitoring Systems, supplied by MiniMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ipro continuous glucose monitoring systems/product/MiniMed Inc
Average 90 stars, based on 1 article reviews
ipro continuous glucose monitoring systems - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cgm device  (International Federation of Clinical Chemistry and Laboratory Medicine)
90
International Federation of Clinical Chemistry and Laboratory Medicine cgm device
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Cgm Device, supplied by International Federation of Clinical Chemistry and Laboratory Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cgm device/product/International Federation of Clinical Chemistry and Laboratory Medicine
Average 90 stars, based on 1 article reviews
cgm device - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
continuous glucose module  (Institute for Clinical Pharmacodynamics)
90
Institute for Clinical Pharmacodynamics continuous glucose module
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Module, supplied by Institute for Clinical Pharmacodynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose module/product/Institute for Clinical Pharmacodynamics
Average 90 stars, based on 1 article reviews
continuous glucose module - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
continuous glucose monitoring  (YSI Inc)
90
YSI Inc continuous glucose monitoring
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Monitoring, supplied by YSI Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring/product/YSI Inc
Average 90 stars, based on 1 article reviews
continuous glucose monitoring - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor (CGM) data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients by WMT. Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.

Journal: Journal of Diabetes

Article Title: Washed microbiota transplantation reduces glycemic variability in unstable diabetes

doi: 10.1111/1753-0407.13485

Figure Lengend Snippet: (A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor (CGM) data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients by WMT. Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.

Article Snippet: Three days before WMT, patients were implanted with a continuous glucose monitor (CGM) device (MeiQi Medical Instruments Co., Ltd., Huzhou, China).

Techniques: Two Tailed Test, Transplantation Assay

Washed microbiota transplantation (WMT) alters profiles of serum metabolites. (A) Heatmap showing changes of serum metabolites determined by non‐targeted metabolomics, n = 11–14. (B) Heatmap of Spearman's correlation coefficients between serum metabolites and glycemic variability (GV) indices. (C) The 8 positively correlated metabolites between fecal and serum compartments. Color range varies from light red (weaker correlation) to dark red (stronger correlation). Statistical methods were the same as stated in Figure . AUC, area under the curve; BG, blood glucose; CGM, continuous glucose monitor; CV, coefficient of variation; HbA1c, glycated hemoglobin; LAGE, largest amplitude of glycemic excursions; MBG, mean blood glucose; PPGE, postprandial glucose excursion; SBMT, steamed bun meal test; SMBG, self‐monitoring of blood glucose; TIR, time in range.

Journal: Journal of Diabetes

Article Title: Washed microbiota transplantation reduces glycemic variability in unstable diabetes

doi: 10.1111/1753-0407.13485

Figure Lengend Snippet: Washed microbiota transplantation (WMT) alters profiles of serum metabolites. (A) Heatmap showing changes of serum metabolites determined by non‐targeted metabolomics, n = 11–14. (B) Heatmap of Spearman's correlation coefficients between serum metabolites and glycemic variability (GV) indices. (C) The 8 positively correlated metabolites between fecal and serum compartments. Color range varies from light red (weaker correlation) to dark red (stronger correlation). Statistical methods were the same as stated in Figure . AUC, area under the curve; BG, blood glucose; CGM, continuous glucose monitor; CV, coefficient of variation; HbA1c, glycated hemoglobin; LAGE, largest amplitude of glycemic excursions; MBG, mean blood glucose; PPGE, postprandial glucose excursion; SBMT, steamed bun meal test; SMBG, self‐monitoring of blood glucose; TIR, time in range.

Article Snippet: Three days before WMT, patients were implanted with a continuous glucose monitor (CGM) device (MeiQi Medical Instruments Co., Ltd., Huzhou, China).

Techniques: Transplantation Assay